Verici Dx raises additional £0.19m through retail offer
12th Jun 2026 11:38
(Sharecast News) - Verici Dx said on Friday that it had raised about £190,000 through its WRAP retail offer, taking total gross proceeds from the offer and an associated placing to approximately £2.6m.
Read moreVerici Dx to raise up to £5m to accelerate diagnostics roll-out
21st Jul 2025 13:07
(Sharecast News) - Verici Dx has announced a proposed equity fundraising of at least £5m on Monday, through a placing, subscription, and retail offer, aimed at accelerating the commercial rollout of its next-generation kidney transplant diagnostics.
Read moreVerici Dx reports record Tutivia orders, downgrades revenue outlook
7th Apr 2025 11:26
(Sharecast News) - Verici Dx has reported its highest-ever quarterly order rate for its Tutivia transplant diagnostic test in an update on Monday, with 292 orders in the first quarter of 2025, representing a 68% increase over the prior quarter, although it revised down its revenue forecasts amid some market delays.
Read moreVerici Dx announces delay to Medicare determination for Tutivia test
11th Oct 2024 11:50
(Sharecast News) - Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced an extension to its timeline for submitting supplemental information to the US Centers for Medicare and Medicaid Services in support of coverage determination for its 'Tutivia' test.
Read moreVerici Dx reaches Thermo Fisher collaboration milestone
1st Jul 2024 13:34
(Sharecast News) - Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced a significant milestone achievement under its agreement with Thermo Fisher Scientific on Monday.
Read moreVerici Dx completes analytical validation on two assays
15th Feb 2022 14:28
(Sharecast News) - Clinical diagnostics developer Verici Dx announced on Tuesday that its two lead in-vitro diagnostic assays, 'Clarava' and 'Tuteva', had completed analytical validation under the CLIA requirements, meeting criteria for robust assay performance.
Read moreVerici Dx enters collaboration with Nasdaq-listed Illumina
5th Jan 2022 12:54
(Sharecast News) - Organ transplant clinical diagnosis developer Verici Dx announced a collaboration with Nasdaq-listed Illumina on Wednesday, to expedite the operational launch of data analysis processing and the predictive artificial intelligence component of its products using early access to Illumina's new software platform ICA.
Read moreVerici granted 'fundamental' codes for tests in US market
4th Jan 2022 16:05
(Sharecast News) - Organ transplant diagnostics company Verici Dx has been granted 'CPT' proprietary laboratory analyses (PLA) codes for both its 'Clarava' and 'Tuteva' tests by the American Medical Association (AMA), it announced on Tuesday.
Read moreVerici enrols patients for multi-centre study ahead of forecast
31st Aug 2021 12:32
(Sharecast News) - Organ transplant diagnostics developer Verici Dx announced on Tuesday that patient enrolment for a multi-centre observational clinical validation study for its lead products had concluded ahead of management expectations.
Read more